Stemline Therapeutics, Inc. (STML) was a big mover last session with its shares rising over 7% on the day. The upside was owing to the company’s announcement of positive top-line results from the lead-in stage of its ongoing SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm. This development led to far more shares changing hands yesterday than in a normal session. This breaks the recent trend of the company as the stock is now trading above the volatile price range of $12.71 to $13.60 since May 11.
This biopharmaceutical company has seen no estimate revision in the last 7 days. The Zacks Consensus Estimate hasn’t been in trend either. Friday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
Stemline Therapeutics currently has a Zacks Rank #3 (Hold).
Investors interested in the biomedical industry may, however, consider Actelion Ltd. (ALIOF) which sports a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment